132 related articles for article (PubMed ID: 3244653)
1. Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application.
Supersaxo A; Hein W; Gallati H; Steffen H
Pharm Res; 1988 Aug; 5(8):472-6. PubMed ID: 3244653
[TBL] [Abstract][Full Text] [Related]
2. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration.
Supersaxo A; Hein WR; Steffen H
Pharm Res; 1990 Feb; 7(2):167-9. PubMed ID: 2137911
[TBL] [Abstract][Full Text] [Related]
3. Effect of interferon-alpha-2a on the output of recirculating lymphocytes from single lymph nodes.
Hein WR; Supersaxo A
Immunology; 1988 Jul; 64(3):469-74. PubMed ID: 3410492
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog.
Gibson DM; Cotler S; Spiegel HE; Colburn WA
J Interferon Res; 1985; 5(3):403-8. PubMed ID: 4056487
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
Wadler S; Goldman M; Lyver A; Wiernik PH
Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.
Hersey P; McLeod GR; Thomson DB
Br J Haematol; 1991 Oct; 79 Suppl 1():60-6. PubMed ID: 1931712
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of recombinant alpha A interferon following I.V. infusion and bolus, I.M., and P.O. administrations to African green monkeys.
Wills RJ; Spiegel HE; Soike KF
J Interferon Res; 1984; 4(3):399-409. PubMed ID: 6491397
[TBL] [Abstract][Full Text] [Related]
9. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection.
Wills RJ; Dennis S; Spiegel HE; Gibson DM; Nadler PI
Clin Pharmacol Ther; 1984 May; 35(5):722-7. PubMed ID: 6713784
[TBL] [Abstract][Full Text] [Related]
10. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a.
Berman E; Heller G; Kempin S; Gee T; Tran LL; Clarkson B
Blood; 1990 Feb; 75(4):839-45. PubMed ID: 2302457
[TBL] [Abstract][Full Text] [Related]
11. The lymphatic route. VI. Distribution of recombinant interferon-alpha 2 in rabbit and pig plasma and lymph.
Bocci V; Pessina GP; Paulesu L; Nicoletti C
J Biol Response Mod; 1988 Aug; 7(4):390-400. PubMed ID: 3171601
[TBL] [Abstract][Full Text] [Related]
12. Differences in murine gut-associated lymphoid tissues in generating broadly nonspecific cytotoxic cells in response to interferon alpha A/D and interleukin 2.
Chikkala NF; Gautam SC
Cell Immunol; 1991 Jul; 135(2):418-30. PubMed ID: 2036676
[TBL] [Abstract][Full Text] [Related]
13. [Human recombinant interferon-alpha 2a polybutylcyanoacrylate sustained release lyophilized nanospheres for liver-targeting].
Lu B; Feng JF; Yang XC
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):1-4. PubMed ID: 14981799
[TBL] [Abstract][Full Text] [Related]
14. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration.
Smith RA; Norris F; Palmer D; Bernhardt L; Wills RJ
Clin Pharmacol Ther; 1985 Jan; 37(1):85-8. PubMed ID: 3965239
[TBL] [Abstract][Full Text] [Related]
15. Human recombinant interferon alpha-2a plus 3'-azido-3'-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells.
Darnowski JW; Davol PA; Goulette FA
Biochem Pharmacol; 1997 Feb; 53(4):571-80. PubMed ID: 9105409
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
Eton O; Talpaz M; Lee KH; Rothberg JM; Brell JM; Benjamin RS
Cancer; 1996 Mar; 77(5):893-9. PubMed ID: 8608480
[TBL] [Abstract][Full Text] [Related]
17. [Adamantiades-Behçet disease. Therapeutic administration of systemic recombinant interferon-alpha-2a].
Zouboulis CC; Treudler R; Orfanos CE
Hautarzt; 1993 Jul; 44(7):440-5. PubMed ID: 8365878
[TBL] [Abstract][Full Text] [Related]
18. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
19. The lymphatic route--II. Pharmacokinetics of human recombinant interferon-alpha 2 injected with albumin as a retarder in rabbits.
Bocci V; Muscettola M; Naldini A; Bianchi E; Segre G
Gen Pharmacol; 1986; 17(1):93-6. PubMed ID: 3949153
[TBL] [Abstract][Full Text] [Related]
20. Selective decrease in Leu8-negative T cell subpopulations following treatment with recombinant interferon-alpha 2a (rIFN-alpha 2a).
Martínez-Maza O; Figlin RA; Giorgi JV; Fahey JL
Cell Immunol; 1988 Nov; 117(1):89-98. PubMed ID: 2902935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
